Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

Investors may be wary of ZYDUSLIFE as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 1.938000
forwardPE 22.764942
debtToEquity 34.305000
earningsGrowth 0.381000
revenueGrowth 0.169000
grossMargins 0.715810
operatingMargins 0.212270
trailingEps 48.930000
forwardEps 0.000000

With a current ratio 1.938, ZYDUSLIFE demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
ZYDUSLIFE's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
ZYDUSLIFE's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that ZYDUSLIFE is expected to continue growing, with rising profits and sales contributing to its long-term success.
ZYDUSLIFE's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Over time, ZYDUSLIFE's price projections have steadily declined, reflecting reduced confidence in the company's future performance. The downward revisions suggest analysts are becoming more conservative in their assessments.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


ZYDUSLIFE stock was bought in 1 transactions, while the market price was at 951.4000244140625.There were no buy transactions during the given timeframe.More sells than buys at ZYDUSLIFE's current price levels suggest potential weakness. If this trend continues, the stock may experience further price declines as selling pressure increases.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Recent analysis shows a strong buy bias for ZYDUSLIFE, encouraging investors to view it as a solid investment option. The positive sentiment surrounding ZYDUSLIFE suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.